

LETTER

Open Access



# COVID-19: room for treating T cell exhaustion?

Giovanni Riva<sup>1†</sup>, Vincenzo Nasillo<sup>2†</sup>, Enrico Tagliafico<sup>1</sup>, Tommaso Trenti<sup>1</sup> and Mario Luppi<sup>2\*</sup> 

Dear Editor,

Immunosuppressive therapy has emerged as promising therapeutic approach in the management of Coronavirus disease-19 (COVID-19) patients, who are often overwhelmed by dysfunctional immune responses [1]. However, some authors highlighted the risk related to unbalanced use of immunosuppressive treatments, since failure of antiviral immunity to control SARS-CoV-2 replication could underlie the hyper-inflammatory responses characterizing severe COVID-19 [2]. In critically ill COVID-19 patients, indeed, massive cytokine storms (including IL-6, TNF- $\alpha$ , and other inflammatory biomarkers), as well as increments of circulating neutrophils and monocyte activation, are typically observed together with low T lymphocyte counts and functional exhaustion of effector T cell responses [1, 3, 4]. Such ineffective and detrimental expansions of innate/humoral responses, alongside T cell suppression, are reminiscent of classical features of sepsis, which is currently defined as a life-threatening organ dysfunction induced by dysregulated host response to infection, being characterized not only by systemic hyperinflammation (SIRS) with related endothelial and organ damage, but also by impairment of adaptive T cell immunity. Moreover, the relevant coagulation disorders observed in end-stage COVID-19 could also well fit with the idea that severe COVID-19 possibly represents a peculiar clinicopathologic manifestation of viral sepsis.

To date, while clinical trials with immunosuppressive treatments (e.g., anti-IL-6 tocilizumab) are ongoing in COVID-19 patients [1], therapeutic approaches to

enhance T cell functions have not yet been attempted in this setting. Importantly, immune checkpoint inhibitors (ICIs), such as anti-PD-1 and anti-PD-L1 monoclonal antibodies, originally developed to improve antineoplastic T cell immunity, are undergoing clinical investigation in septic patients [5]. Thus, it should be conceivable that, also in COVID-19 patients, ICIs may be tested to restore immune competence of exhausted T cell subsets and, in this context, to specifically improve the pivotal process of virus elimination, likely blunted in severe COVID-19. Of course, as for septic patients, the risk of immune-mediated complications (including inflammatory flares, pneumonitis, and systemic cytokine-release syndrome) could raise some concerns about the use of ICIs in COVID-19 patients. However, it should be noted that (i) autoimmune-like adverse events were not clinically evident in septic patients treated with ICIs [5] and (ii) tocilizumab represents a standard treatment for the management of such complications in cancer patients and could be promptly associated with ICIs in COVID-19 patients. While awaiting for the development of effective antivirals and vaccines against this life-threatening coronavirus, we could harness the opportunity to try tuning patients' immune system by using different immunomodulatory strategies now available, aiming to obtain more proper immune responses to SARS-CoV-2 infection and, hopefully, to reduce COVID-19-related mortality.

#### Acknowledgements

Not applicable.

#### Authors' contributions

Conception and writing: G.R., V.N., and M.L. Critical revision: E.T. and T.T. Final approval: G.R., V.N., E.T., T.T., and M.L.

#### Funding

Not applicable.

\* Correspondence: [mario.luppi@unimore.it](mailto:mario.luppi@unimore.it)

<sup>†</sup>Giovanni Riva and Vincenzo Nasillo contributed equally to this work.

<sup>2</sup>Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Hematology Unit, AOU Policlinico di Modena, Via Del Pozzo 71, 41124 Modena, Italy

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

**Availability of data and materials**

Not applicable.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Written informed consent for publication was obtained from all participants.

**Competing interests**

The authors declared that they have no conflicts of interest to this work.

**Author details**

<sup>1</sup>Department of Laboratory Medicine and Pathology, AUSL/AOU Policlinico, Modena, Italy. <sup>2</sup>Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Hematology Unit, AOU Policlinico di Modena, Via Del Pozzo 71, 41124 Modena, Italy.

Received: 27 April 2020 Accepted: 8 May 2020

Published online: 15 May 2020

**References**

1. Cao X. COVID-19: immunopathology and its implications for therapy. *Nat Rev Immunol.* 2020;1–2. <https://doi.org/10.1038/s41577-020-0308-3>. [Epub ahead of print] PMID: PMC7143200.
2. Ritchie AI, Singanayagam A. Immunosuppression for hyperinflammation in COVID-19: a double-edged sword? *Lancet.* 2020;395(10230):1111. [https://doi.org/10.1016/S0140-6736\(20\)30691-7](https://doi.org/10.1016/S0140-6736(20)30691-7). PMID: 32220278.
3. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. *Clin Infect Dis.* 2020. <https://doi.org/10.1093/cid/ciaa248>. [Epub ahead of print] PMID: 32161940.
4. Moon C. Fighting COVID-19 exhausts T cells. *Nat Rev Immunol.* 2020;1. <https://doi.org/10.1038/s41577-020-0304-7>. [Epub ahead of print] PMID: PMC7132550.
5. Shankar-Hari M, Fish M, Azoulay E. Should we consider blocking the inhibitory immune checkpoint molecules for treating T cell exhaustion in sepsis? *Intensive Care Med.* 2020;46(1):119–21. <https://doi.org/10.1007/s00134-019-05814-8>. PMID: 31659386.

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.